Mary E. Rinella

3.4k total citations · 2 hit papers
10 papers, 254 citations indexed

About

Mary E. Rinella is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Physiology. According to data from OpenAlex, Mary E. Rinella has authored 10 papers receiving a total of 254 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 3 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Physiology. Recurrent topics in Mary E. Rinella's work include Liver Disease Diagnosis and Treatment (8 papers), Liver Diseases and Immunity (2 papers) and Liver Disease and Transplantation (2 papers). Mary E. Rinella is often cited by papers focused on Liver Disease Diagnosis and Treatment (8 papers), Liver Diseases and Immunity (2 papers) and Liver Disease and Transplantation (2 papers). Mary E. Rinella collaborates with scholars based in United States, United Kingdom and France. Mary E. Rinella's co-authors include Philip N. Newsome, Iris Kliers, Michael Roden, Elisabetta Bugianesi, Vlad Ratziu, Mette Skalshøi Kjær, Michelle T. Long, Arun J. Sanyal, Kristiane A. Engebretsen and Hee Yeon Kim and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Hepatology.

In The Last Decade

Mary E. Rinella

7 papers receiving 246 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

2025 170 citations Philip N. Newsome, Iris Kliers et al. New England Journal of Medicine profile →
Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial

2024 63 citations Philip N. Newsome, Arun J. Sanyal et al. Alimentary Pharmacology & Therapeutics profile →

Peers

Mary E. Rinella

EPIDE

EDM

SURGE

PHYSI

HEPAT

Samina Ajaz Hussain United States

Yansong Lin China

Soroor Owrangi United States

Kazuhide Ishikura Japan

Valentina Peta France

M. Christofi United States

Nicole Aumann Germany

Mats Kvarnström Sweden

Magnus Holmer Sweden

Josh Bilson United Kingdom

Samina Ajaz Hussain United States

Mary E. Rinella

168 ×1.1

EPIDE

171 ×1.4

EDM

58 ×1.3

SURGE

56 ×1.4

PHYSI

45 ×1.2

HEPAT

Citations per year, relative to Mary E. Rinella Mary E. Rinella (= 1×) peers Samina Ajaz Hussain

Countries citing papers authored by Mary E. Rinella

Since Specialization

Citations

This map shows the geographic impact of Mary E. Rinella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary E. Rinella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary E. Rinella more than expected).

Fields of papers citing papers by Mary E. Rinella

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary E. Rinella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary E. Rinella. The network helps show where Mary E. Rinella may publish in the future.

Co-authorship network of co-authors of Mary E. Rinella

This figure shows the co-authorship network connecting the top 25 collaborators of Mary E. Rinella. A scholar is included among the top collaborators of Mary E. Rinella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary E. Rinella. Mary E. Rinella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Rinella, Mary E., et al.. (2026). MASLD as a complication of obesity must include liver risk stratification. Nature Medicine. 32(1). 18–19.

2.

Torp, Nikolaj, Mads Israelsen, Maja Thiele, Mary E. Rinella, & Aleksander Krag. (2025). Phosphatidylethanol in steatotic liver disease. Journal of Hepatology. 83(5). 1189–1203. 3 indexed citations

3.

Kim, Hee Yeon & Mary E. Rinella. (2025). Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment. Clinical and Molecular Hepatology. 31(3). 753–770. 6 indexed citations

4.

Celsa, Ciro, Grazia Pennisi, Marco Enea, et al.. (2025). Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. The Lancet. Gastroenterology & hepatology. 10(11). 998–1012.

5.

Newsome, Philip N., Iris Kliers, Michelle T. Long, et al.. (2025). Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine. 392(21). 2089–2099. 170 indexed citations breakdown →

6.

Castéra, Laurent, Mary E. Rinella, & Emmanuel Tsochatzis. (2025). Noninvasive Assessment of Liver Fibrosis. New England Journal of Medicine. 393(17). 1715–1729. 1 indexed citations

7.

Noureddin, Mazen, Mary E. Rinella, Naga Chalasani, et al.. (2025). GS-012 Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, doubleblind, placebo-controlled, phase 2b trial (SYMMETRY). Journal of Hepatology. 82. S8–S9.

8.

Newsome, Philip N., Arun J. Sanyal, Kristiane A. Engebretsen, et al.. (2024). Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Alimentary Pharmacology & Therapeutics. 60(11-12). 1525–1533. 63 indexed citations breakdown →

9.

Forsgren, Mikael, et al.. (2024). Body composition and muscle composition phenotypes in patients on waitlist and shortly after liver transplant – results from a pilot study. BMC Gastroenterology. 24(1). 356–356. 1 indexed citations

10.

Rinella, Mary E. & Arun J. Sanyal. (2006). Intensive Management of Hepatic Failure. Seminars in Respiratory and Critical Care Medicine. 27(3). 241–261. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact